Becker muscular dystrophy (BMD) is a genetic muscle-wasting disease caused by mutations in the DMD gene on the X chromosome, the same gene responsible for Duchenne muscular dystrophy. The difference is how much dystrophin protein survives the mutation. In Duchenne, the mutation shifts the genetic reading frame and almost no working dystrophin is made. In Becker, the mutation usually leaves the reading frame intact, so muscle cells produce a shortened dystrophin that still does part of its job. The result is a milder, slower, far more variable disease: men with BMD typically stay walking well past adolescence, and some remain ambulatory into their sixties.
That distinction matters here, because Becker is where myostatin inhibition was first tested in humans with a muscular dystrophy, and where follistatin gene therapy had its first clinical run. Neither has produced an approved drug. What follows is what the record shows.
What causes Becker muscular dystrophy
DMD is the largest gene in the human genome, and most pathogenic changes in it are deletions or duplications of whole exons. Whether the resulting disease looks like Duchenne or Becker depends on the reading frame. According to GeneReviews, variants that do not alter the reading frame generally correlate with the milder Becker phenotype, while out-of-frame variants generally correlate with Duchenne.
The rule is useful but not absolute. GeneReviews puts its predictive accuracy at 91% to 92% in young children with simplex cases, and notes exceptions in roughly 15% of BMD deletions and 30% to 34% of BMD duplications. This is why two men with mutations in the same region can have very different courses, and why a genetic report alone does not tell a family how the next twenty years will go.
Because DMD sits on the X chromosome, BMD overwhelmingly affects males. Female carriers can have elevated creatine kinase and, less often, cardiac involvement or muscle symptoms of their own.
How Becker differs from Duchenne
The clinical dividing line used in the literature is the age at loss of independent walking: before age 13 in Duchenne, after age 16 in Becker, with an intermediate group losing ambulation between 13 and 16. Duchenne is usually diagnosed around age four to five after delayed motor milestones; Becker often surfaces much later, sometimes after an incidental finding of raised creatine kinase, muscle cramps with exercise, or dark urine after exertion.
Incidence figures vary by population and ascertainment method. A northern England study cited in GeneReviews found BMD in about 1 in 18,450 live male births; other estimates place it nearer 1 in 30,000. The true figure is uncertain partly because mild cases go undiagnosed for decades.
For a comparison of how myostatin biology has been studied in the more severe condition, see our overview of myostatin in Duchenne muscular dystrophy. BMD is also frequently confused with other adult-onset dystrophies, and distinguishing it from limb-girdle muscular dystrophy usually requires genetic testing rather than examination alone.
Symptoms, progression, and the cardiac problem
Weakness in BMD typically begins in the hip and thigh muscles, producing difficulty with stairs, rising from the floor, and running. Calf hypertrophy is common. Progression is slow but uneven: many patients are stable for years, then decline over a short window.
The most consequential feature is cardiac. Dystrophin is expressed in heart muscle, and dilated cardiomyopathy is a leading cause of death in BMD. GeneReviews reports a mean age of death in the mid-40s, with heart failure the most common cause. Cardiac involvement does not track neatly with skeletal muscle weakness, which is why cardiology follow-up is recommended even for men whose walking is good.
How Becker muscular dystrophy is diagnosed
Serum creatine kinase is usually elevated, above five times normal in BMD males per GeneReviews, versus more than ten times normal in Duchenne. High CK prompts genetic testing, which is now the diagnostic backbone: deletion and duplication analysis of DMD first, which detects 65% to 80% of pathogenic variants, followed by sequence analysis, which detects a further 20% to 35%. Muscle biopsy with western blot and immunohistochemistry is still warranted when molecular testing comes back negative but suspicion remains. For coding and record-keeping questions, see our note on muscular dystrophy ICD-10 codes.
What myostatin has to do with Becker muscular dystrophy
Myostatin restrains muscle growth. The reasoning in the 2000s was straightforward: if you block it in a dystrophic muscle, you get more muscle to compensate for the fragile membrane. Becker patients, being adults with slow progression, were an obvious first test population.
The first human test was MYO-029 (stamulumab), a neutralizing anti-myostatin antibody. Its phase I/II trial enrolled 116 adults with Becker muscular dystrophy, facioscapulohumeral dystrophy, or limb-girdle muscular dystrophy, in dose-escalation cohorts at 1, 3, 10, and 30 mg/kg. Safety and tolerability were good apart from cutaneous hypersensitivity at the two highest doses. There were no improvements in the exploratory endpoints of muscle strength or function, though the authors state clearly that the study was not powered to detect efficacy. Bioactivity was supported by a trend toward increased muscle size on DEXA and muscle histology in a limited number of subjects. Development did not continue. The broader class is covered in our page on anti-myostatin antibodies.
The second attempt used follistatin, myostatin's natural antagonist, delivered as gene therapy. In a phase 1/2a trial, AAV1.CMV.FS344 was injected directly into both quadriceps of six men with BMD. In the low-dose cohort (3 × 10¹¹ vg/kg/leg), two patients improved on the six-minute walk test by 58 and 125 meters and one showed no change. In the higher-dose cohort (6 × 10¹¹ vg/kg/leg), two improved by 108 and 29 meters and one did not. No adverse effects were reported, and biopsies showed reduced endomysial fibrosis, reduced central nucleation, and muscle hypertrophy. Six patients, an open-label design, and a variable walk test make this a proof-of-principle result and nothing more, which is how the authors framed it. Background on the delivery approach is in our page on follistatin gene therapy.
The same logic was later tested in Duchenne with a more potent agent. In a phase 2 trial of 120 boys treated with domagrozumab or placebo, there was no significant difference in the total number of NSAA motor skills gained or lost at week 49, and the program did not go on to approval.
The counterintuitive myostatin finding in Becker
Here the biology inverts the marketing. A four-year prospective natural history study of 34 BMD patients across 106 visits measured serum myostatin by ELISA alongside creatine kinase and the creatine/creatinine ratio. Myostatin correlated positively and strongly with functional performance: rho values of 0.792 to 0.842 against the North Star Ambulatory Assessment, ten-meter run velocity, and six-minute walk test, all p < 0.001. In other words, lower circulating myostatin was associated with worse motor function, not better.
This makes sense once you remember where myostatin comes from. It is secreted by skeletal muscle, so the amount in blood partly reflects how much muscle is left. In a wasting disease, falling myostatin is a readout of lost muscle mass rather than a therapeutic win. The same study found CK was not associated with performance at all and declined with age. Anyone interpreting a myostatin blood test in the context of muscle disease needs this framing.
It also complicates the drug thesis. If circulating myostatin is already low in advanced BMD, there is less signal left to block, which may be part of why blanket myostatin inhibition has underperformed in dystrophies while showing more promise where muscle is structurally normal.
What is actually in development for Becker now
There is no FDA-approved therapy for Becker muscular dystrophy. Care is supportive: physiotherapy, cardiac and respiratory surveillance, and orthopedic management.
The candidate closest to a decision works by the opposite logic to myostatin inhibition. Sevasemten (formerly EDG-5506) is an oral fast skeletal myosin inhibitor designed to reduce the force of contraction in fast muscle fibers and so limit contraction-induced damage. It aims to protect muscle rather than grow it.
In the phase 2 CANYON trial, 40 adults and 29 adolescents were randomized to sevasemten or placebo for 12 months. The trial met its primary endpoint: a 28% average decrease in creatine kinase versus placebo over months 6 through 12 (p = 0.02). Plasma fast skeletal muscle troponin I fell 77% versus placebo (p < 0.001). The key secondary functional endpoint did not reach significance, with a between-group NSAA difference of 1.1 points favoring sevasemten (p = 0.16); the trial was not powered for functional endpoints, the placebo group numbered 12, and the treatment group had more advanced disease at baseline.
In June 2025 the FDA declined accelerated approval on the CANYON data, calling a single phase 2 study insufficient, while affirming that NSAA can serve as a clinically meaningful endpoint for traditional approval. The pivotal GRAND CANYON cohort (NCT05291091, total study enrollment 244 males aged 12 to 50) is fully enrolled, with topline data expected in the fourth quarter of 2026. Long-term extension data reported by the sponsor in March 2026 showed NSAA essentially flat against a predicted natural-history decline, but open-label results measured against modeled natural history are not the same evidence as a placebo-controlled result. GRAND CANYON is the readout that will matter.
Frequently asked questions
Is Becker muscular dystrophy fatal? It shortens life, primarily through cardiac disease. GeneReviews reports a mean age of death in the mid-40s with heart failure the most common cause, but the range is wide and some men live a normal lifespan. Cardiac monitoring is the single most important part of long-term care.
Can myostatin inhibitors treat Becker muscular dystrophy? No myostatin inhibitor is approved for BMD. The one antibody trial that included BMD patients showed acceptable safety but no improvement in strength or function, and follistatin gene therapy has only been tested in six patients in an open-label study. Anything sold direct-to-consumer as a myostatin blocker has not been tested for this disease.
Is Becker muscular dystrophy the same as Duchenne? Same gene, different consequence. Duchenne mutations usually disrupt the reading frame and abolish dystrophin; Becker mutations usually preserve it and produce a shortened but partly functional protein. The practical dividing line used clinically is loss of walking before age 13 versus after age 16.
Do women get Becker muscular dystrophy? It is an X-linked condition affecting mainly males. Female carriers may have elevated creatine kinase and, in a minority, cardiac involvement or muscle symptoms, so carrier evaluation including cardiac assessment is worth discussing with a genetics service.
What treatments are available today? No disease-modifying drug is approved. Management is supportive and multidisciplinary. Sevasemten is the furthest-advanced investigational candidate, with pivotal data expected in late 2026. Trial participation and medication decisions belong with a neuromuscular specialist.
This article is educational and does not provide medical advice. Dosing and treatment decisions in muscular dystrophy belong to a prescribing clinician.